Bruce Addis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bruce Addis has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ajit Narayanan
School of Engineering, Computer and Mathematical Sciences, Auckland University of Technology, Auckland 1010, New Zealand
1 shared publication - D.Hadji Yiannakis
Departments of Thoracic Surgery, Oncology and Pathology, Derriford Hospital, Plymouth, UK
1 shared publication - Francis G Gabriel
Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK
1 shared publication - Ian A. Cree
Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
1 shared publication - Joseph Rahamim
Departments of Thoracic Surgery, Oncology and Pathology, Derriford Hospital, Plymouth, UK
1 shared publication - Katharine Peregrin
Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK
1 shared publication
Latest Publications
- Open Access
- 27 August 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 300
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
NSCLC exhibits considerable heterogeneity in its sensitivity to chemotherapy and similar heterogeneity is noted in vitro in a variety of model systems. This study has tested the hypothesis that the molecular basis of the observed in vitro chemosensitivity of NSCLC lies within the known resistance mechanisms inherent to these patients' tumors.
- 27 August 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 300
Open AccessResistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
NSCLC exhibits considerable heterogeneity in its sensitivity to chemotherapy and similar heterogeneity is noted in vitro in a variety of model systems. This study has tested the hypothesis that the molecular basis of the observed in vitro chemosensitivity of NSCLC lies within the known resistance mechanisms inherent to these patients' tumors.